Delving into the Latest Updates on pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) with Synapse

Overview

Basic Info

Drug Type

Shared antigen vaccine, DNA vaccine, Therapeutic vaccine

Synonyms-

Target

HPV E7

Action

modulators

Mechanism

E7 modulators(HPV E7 modulators)

Therapeutic Areas

NeoplasmsMouth and Tooth DiseasesOtorhinolaryngologic Diseases

Active Indication-

Inactive Indication

Oropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and Neck

Originator Organization

Ichor Medical Systems, Inc.

Active Organization-

Inactive Organization

Ichor Medical Systems, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated cancer cells. In addition to giving the vaccine using an electroporation device, we are giving the vaccine in combination with an immunomodulatory agent to further enhance immune responses against HPV-infected and associated cancer cells.

Start Date01 Apr 2012

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT00988559

/ CompletedPhase 1IIT

A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups. Subjects enrolled in the first two groups will receive vaccination intradermally with a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.

Start Date01 Sep 2009

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+2]

100 Clinical Results associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)

Login to view more data

100 Translational Medicine associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)

Login to view more data

100 Patents (Medical) associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)

Login to view more data

100 Deals associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Oropharyngeal Neoplasms	Phase 1	United States	Ichor Medical Systems, Inc.	01 Apr 2012
Squamous Cell Carcinoma of Head and Neck	Phase 1	United States	Ichor Medical Systems, Inc.	01 Apr 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00988559 (CTgov)	Phase 1	Cervical Intraepithelial Neoplasia	132	Gene gun vaccine+DNA vaccination (PMED Delivery - Groups 1 and 2)	rviulwwffn = vyefspiuka kkudjpivug (kteuqvzfqu, ezltpgzyvg - tlhawvzxtv) View more	-	09 Jul 2018
				therapeutic resection of the lesion+DNA vaccination+intramuscular vaccination (IM Injections - Groups 5 and 6)	rviulwwffn = mlbsbsociw kkudjpivug (kteuqvzfqu, jlnusklnmi - aeegunuzkl) View more